Celladon Corp (CLDN) 11.94 $CLDN
Celadon Trucking Awarded 2013 Gold Carrier of the Year by Lowe's
PR Newswire - Wed Apr 16, 1:35PM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced that it was recently recognized by home improvement retailer Lowe's Companies, Inc. with its prestigious Gold Carrier of the Year award. To achieve Gold status, carriers must exceed an overall 98% on-time performance, shipment status compliance and freight acceptance. In addition to carrier metrics, Lowe's also factors in outstanding customer service and value-added supply chain solutions provided by carriers. This is the second year in a row that Celadon has earned the esteemed Gold designation for consistently exceeding the transportation and logistics demands established by Lowe's.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Celladon Corp. Shares Are Pumped Up
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 10, 12:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celladon , a clinical-stage...
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and where preliminary clinical evidence suggests it provides a substantial improvement over existing therapies. Celladon is developing MYDICAR as a novel, first-in-class therapy for patients with chronic heart failure due to systolic dysfunction. MYDICAR uses genetic enzyme replacement therapy to correct the deficiency in the enzyme SERCA2a, which is an enzyme that becomes deficient in heart failure patients and results in inadequate pumping of the heart. Celladon has developed a companion diagnostic to identify the patients who are AAV1 NAb negative and therefore eligible for MYDICAR treatment.
Celadon Group, Inc. Announces Dates For Earnings Release And Conference Call
PR Newswire - Tue Apr 08, 9:58AM CDT
Celadon Group, Inc. (NYSE: CGI) will release its fiscal 2014 third quarter results on Tuesday, April 29 after the close of the market. A conference call to discuss the quarter will be held on Wednesday, April 30 at 11:00 a.m. Eastern Time.
Celadon Group, Inc. Announces The Sale Of Lease Portfolio Assets And Earnings Release Date
PR Newswire - Tue Apr 01, 11:39AM CDT
Celadon Group, Inc. (NYSE:CGI) ("Celadon"
announced today that it has agreed to sell its independent contractor lease portfolio and associated assets to Element Financial Corporation (TSX:EFN) ("Element". The existing portfolio includes approximately 600 leases and tractors that are currently in service with independent contractors with Celadon and other partner carriers. The purchase price of the transaction is approximately $53 million, which the company expects to use the funds to pay down its bank line. As part of this transaction, the company has also entered into a Program Agreement with Element under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon.
Celladon (CLDN) Jumps: Stock Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:39AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 6% on the day.
Celladon Added to the Russell 2000(R) and Russell 3000(R) Indexes
GlobeNewswire - Tue Apr 01, 6:03AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that effective as of the close of the market on Monday, March 31, 2014, the Company was added to the Russell 2000(R) and the Russell 3000(R) indexes, as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.
Element Enters Multi-Year Program Agreement With Celadon Group and Acquires US$53 Million Lease Portfolio
Marketwire - Tue Apr 01, 6:02AM CDT
Element Financial Corporation (TSX: EFN) ("Element" or the "Company", one of North America's leading equipment finance companies, announced today that it has entered into a multi-year Program Agreement (the "Program Agreement" with Indianapolis-based Celadon Group, Inc. ("Celadon", one of the largest and most progressive transportation and logistics companies in North America, under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon.
Celladon Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced financial results for the quarter and year ended December 31, 2013.
Celladon to Report Fourth Quarter and Year-End 2013 Results on Monday, March 31, 2014
GlobeNewswire - Fri Mar 21, 6:00AM CDT
-- Investor Call Scheduled for 4:30pm Eastern on Monday, March 31, 2014
Celladon to Present at BioCentury's Future Leaders in the Biotech Industry Conference
GlobeNewswire - Thu Mar 20, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that Krisztina Zsebo, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Future Leaders in the Biotech Industry conference, being held at the Millennium Hotel in New York city on Friday, March 28, 2014.
Celadon Trucking Awarded 2013 Gold Carrier of the Year by Lowe's
PR Newswire - Wed Apr 16, 1:35PM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced that it was recently recognized by home improvement retailer Lowe's Companies, Inc. with its prestigious Gold Carrier of the Year award. To achieve Gold status, carriers must exceed an overall 98% on-time performance, shipment status compliance and freight acceptance. In addition to carrier metrics, Lowe's also factors in outstanding customer service and value-added supply chain solutions provided by carriers. This is the second year in a row that Celadon has earned the esteemed Gold designation for consistently exceeding the transportation and logistics demands established by Lowe's.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Celladon Corp. Shares Are Pumped Up
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 10, 12:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celladon , a clinical-stage...
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and where preliminary clinical evidence suggests it provides a substantial improvement over existing therapies. Celladon is developing MYDICAR as a novel, first-in-class therapy for patients with chronic heart failure due to systolic dysfunction. MYDICAR uses genetic enzyme replacement therapy to correct the deficiency in the enzyme SERCA2a, which is an enzyme that becomes deficient in heart failure patients and results in inadequate pumping of the heart. Celladon has developed a companion diagnostic to identify the patients who are AAV1 NAb negative and therefore eligible for MYDICAR treatment.
Celadon Group, Inc. Announces Dates For Earnings Release And Conference Call
PR Newswire - Tue Apr 08, 9:58AM CDT
Celadon Group, Inc. (NYSE: CGI) will release its fiscal 2014 third quarter results on Tuesday, April 29 after the close of the market. A conference call to discuss the quarter will be held on Wednesday, April 30 at 11:00 a.m. Eastern Time.
Celadon Group, Inc. Announces The Sale Of Lease Portfolio Assets And Earnings Release Date
PR Newswire - Tue Apr 01, 11:39AM CDT
Celadon Group, Inc. (NYSE:CGI) ("Celadon"
announced today that it has agreed to sell its independent contractor lease portfolio and associated assets to Element Financial Corporation (TSX:EFN) ("Element". The existing portfolio includes approximately 600 leases and tractors that are currently in service with independent contractors with Celadon and other partner carriers. The purchase price of the transaction is approximately $53 million, which the company expects to use the funds to pay down its bank line. As part of this transaction, the company has also entered into a Program Agreement with Element under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon. Celladon (CLDN) Jumps: Stock Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:39AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 6% on the day.
Celladon Added to the Russell 2000(R) and Russell 3000(R) Indexes
GlobeNewswire - Tue Apr 01, 6:03AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that effective as of the close of the market on Monday, March 31, 2014, the Company was added to the Russell 2000(R) and the Russell 3000(R) indexes, as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.
Element Enters Multi-Year Program Agreement With Celadon Group and Acquires US$53 Million Lease Portfolio
Marketwire - Tue Apr 01, 6:02AM CDT
Element Financial Corporation (TSX: EFN) ("Element" or the "Company"
, one of North America's leading equipment finance companies, announced today that it has entered into a multi-year Program Agreement (the "Program Agreement" with Indianapolis-based Celadon Group, Inc. ("Celadon", one of the largest and most progressive transportation and logistics companies in North America, under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon. Celladon Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced financial results for the quarter and year ended December 31, 2013.
Celladon to Report Fourth Quarter and Year-End 2013 Results on Monday, March 31, 2014
GlobeNewswire - Fri Mar 21, 6:00AM CDT
-- Investor Call Scheduled for 4:30pm Eastern on Monday, March 31, 2014
Celladon to Present at BioCentury's Future Leaders in the Biotech Industry Conference
GlobeNewswire - Thu Mar 20, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that Krisztina Zsebo, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Future Leaders in the Biotech Industry conference, being held at the Millennium Hotel in New York city on Friday, March 28, 2014.
